RhumbLine Advisers’s Insulet PODD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25.2M Buy
165,210
+7,742
+5% +$1.29M 0.02% 649
2026
Q1
$33M Buy
157,468
+1,440
+0.9% +$362K 0.03% 509
2025
Q4
$44.3M Buy
156,028
+3,587
+2% +$1.12M 0.04% 402
2025
Q3
$47.1M Sell
152,441
-2,540
-2% -$796K 0.04% 383
2025
Q2
$48.7M Buy
154,981
+2,099
+1% +$606K 0.04% 366
2025
Q1
$40.1M Buy
152,882
+10,135
+7% +$2.74M 0.04% 412
2024
Q4
$37.3M Sell
142,747
-2,242
-2% -$565K 0.03% 432
2024
Q3
$33.7M Sell
144,989
-1,572
-1% -$323K 0.03% 469
2024
Q2
$29.6M Buy
146,561
+757
+0.5% +$136K 0.03% 494
2024
Q1
$25M Buy
145,804
+714
+0.5% +$133K 0.02% 586
2023
Q4
$31.5M Sell
145,090
-380
-0.3% -$65.2K 0.03% 464
2023
Q3
$23.2M Sell
145,470
-3,385
-2% -$758K 0.03% 553
2023
Q2
$42.9M Sell
148,855
-2,722
-2% -$827K 0.05% 341
2023
Q1
$48.3M Buy
151,577
+66,814
+79% +$19.8M 0.06% 294
2022
Q4
$25M Buy
84,763
+4,329
+5% +$1.19M 0.03% 482
2022
Q3
$18.5M Buy
80,434
+3,155
+4% +$790K 0.03% 564
2022
Q2
$16.8M Buy
77,279
+9,065
+13% +$2.06M 0.02% 621
2022
Q1
$18.2M Sell
68,214
-3,314
-5% -$813K 0.02% 633
2021
Q4
$19M Buy
71,528
+1,504
+2% +$436K 0.02% 651
2021
Q3
$19.9M Sell
70,024
-515
-0.7% -$147K 0.03% 591
2021
Q2
$19.4M Sell
70,539
-4,142
-6% -$1.13M 0.03% 617
2021
Q1
$19.5M Sell
74,681
-3,169
-4% -$849K 0.03% 596
2020
Q4
$19.9M Sell
77,850
-2,576
-3% -$639K 0.03% 545
2020
Q3
$19M Sell
80,426
-2,385
-3% -$502K 0.03% 492
2020
Q2
$16.1M Buy
82,811
+17,858
+27% +$3.41M 0.03% 542
2020
Q1
$10.8M Sell
64,953
-681
-1% -$124K 0.02% 638
2019
Q4
$11.2M Buy
65,634
+1,668
+3% +$278K 0.02% 760
2019
Q3
$10.6M Sell
63,966
-291
-0.5% -$40.9K 0.02% 751
2019
Q2
$7.67M Sell
64,257
-5,244
-8% -$538K 0.01% 934
2019
Q1
$6.61M Sell
69,501
-61
-0.1% -$5.23K 0.01% 1014
2018
Q4
$5.52M Sell
69,562
-2,598
-4% -$220K 0.01% 1042
2018
Q3
$7.64M Sell
72,160
-1,324
-2% -$124K 0.01% 827
2018
Q2
$6.3M Buy
73,484
+6,279
+9% +$563K 0.01% 946
2018
Q1
$5.83M Sell
67,205
-1,957
-3% -$152K 0.01% 938
2017
Q4
$4.77M Sell
69,162
-9,878
-12% -$648K 0.01% 1096
2017
Q3
$4.35M Buy
79,040
+326
+0.4% +$17.8K 0.01% 1114
2017
Q2
$4.04M Sell
78,714
-1,351
-2% -$58.7K 0.01% 1130
2017
Q1
$3.45M Buy
80,065
+2,092
+3% +$89.7K 0.01% 1237
2016
Q4
$2.94M Buy
77,973
+2,561
+3% +$95.4K 0.01% 1221
2016
Q3
$3.09M Buy
75,412
+1,727
+2% +$68.3K 0.01% 1146
2016
Q2
$2.23M Buy
73,685
+2,243
+3% +$69.8K 0.01% 1272
2016
Q1
$2.37M Buy
71,442
+1,320
+2% +$41.4K 0.01% 1246
2015
Q4
$2.65M Buy
70,122
+3,850
+6% +$130K 0.01% 1172
2015
Q3
$1.72M Buy
66,272
+2,022
+3% +$61.3K 0.01% 1413
2015
Q2
$1.99M Sell
64,250
-1,455
-2% -$42.9K 0.01% 1412
2015
Q1
$2.19M Buy
65,705
+7,380
+13% +$249K 0.01% 1345
2014
Q4
$2.69M Sell
58,325
-2,344
-4% -$100K 0.01% 1158
2014
Q3
$2.24M Sell
60,669
-240
-0.4% -$8.76K 0.01% 1236
2014
Q2
$2.42M Sell
60,909
-862
-1% -$33.1K 0.01% 1250
2014
Q1
$2.93M Sell
61,771
-3,020
-5% -$134K 0.01% 1112
2013
Q4
$2.4M Buy
64,791
+770
+1% +$28.4K 0.01% 1258
2013
Q3
$2.32M Sell
64,021
-983
-2% -$33K 0.01% 1245
2013
Q2
$2.04M Buy
+65,004
New +$1.84M 0.01% 1294

Other funds holding PODD

RhumbLine Advisers's PODD Position: Q2 2026 in Review

RhumbLine Advisers increased its Insulet (PODD) stake by 4.9% in Q2 2026, buying an estimated $1.29M and bringing the position to 165,210 shares worth $25.2M. The position accounts for 0.02% of the portfolio, ranked #649.

RhumbLine Advisers first reported a position in PODD in Q2 2013 and has held it in 53 quarters since. The position peaked at $48.7M in Q2 2025. 569 funds tracked by Wall St. Rank hold PODD as of Q2 2026.

  • RhumbLine Advisers held 165,210 shares of Insulet worth $25.2M as of Q2 2026.
  • RhumbLine Advisers bought 7,742 Insulet shares in Q2 2026, an estimated $1.29M.
  • Insulet made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #649 holding.
  • RhumbLine Advisers first reported a position in Insulet in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Insulet position peaked at $48.7M in Q2 2025.
  • 569 funds tracked by Wall St. Rank held Insulet as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.